News Release

Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. This designation builds on the Orphan Drug Designation that ReAlta received from the U.S. Food and Drug Administration (FDA) Office of Orphan Drug Products earlier this year.

There is an urgent need for new therapeutic options to treat hypoxic-ischemic encephalopathy, a devastating condition that has a profound impact on newborns and their families,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “ReAlta is committed to supporting this vulnerable population and bringing forward the first pharmacological therapy for the treatment of HIE. The Orphan Drug Designation is recognition that RLS-0071 may be an important therapeutic option for this rare but serious condition.”

The EMA grants orphan status to medicinal products intended to treat rare disorders that affect fewer than 5 people per 10,000 in the European Union (EU). The designation provides certain benefits to the drug developer, including ten years of market exclusivity upon marketing authorization, fee reductions, and scientific advice during clinical development.

ReAlta intends to submit an Investigational New Drug (IND) application to the FDA for HIE in 2021 and begin HIE Phase 2 studies in neonates in the U.S., followed by a clinical trial application (CTA) to the EMA in support of phase 2 studies in Europe.

About Neonatal Encephalopathy

Neonatal encephalopathy is also known as hypoxic ischemic encephalopathy (HIE) or neonatal brain asphyxia. In this disease, otherwise normal healthy infants suffer from oxygen starvation to the brain. This can be caused by several processes, including placental tear or tight cord around the neck. These infants are typically otherwise healthy, and the event is abrupt and unanticipated. Many of these infants will die after birth or suffer permanent, life-long brain damage, such as severe mental retardation, or cerebral palsy, or both. HIE is frequently emotionally and financially devastating for the families of HIE babies. Worldwide, HIE is among the top three causes of infant death. The current state-of-the-art treatment for HIE is therapeutic hypothermia; there are currently no pharmacological therapies approved for HIE.

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a clinical stage biotech company dedicated to harnessing the power of the immune system through its EPICC technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. The peptide family leverages one billion years of evolution that has enabled the human astrovirus to inhibit components of the innate immune system. This novel class of therapeutics exploits the virus’ dual targeting approach and enables the rebalancing of complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

Contact:

Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, Inc.
212-213-0006 ext. 315 / 364
Rimai@burnsmc.com / rflamm@burnsmc.com